FDA Approves Genentech ’s Actemra (tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome

South San Francisco, CA -- August 30, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra ® (tocilizumab) intravenous injection for the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news